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CORRECTION
Correction: Clinical Impact of MALDI-TOF MS
Identificationand Rapid Susceptibility
Testing on Adequate Antimicrobial
Treatment in Sepsis with Positive Blood
Cultures
Alexia Verroken, Lydwine Defourny, Olivier le Polain de Waroux, Leïla Belkhir, Pierre-
Franc¸ois Laterre, Michel Delme´e, Youri Glupczynski
There are numerical errors in the first and penultimate sentences of the second paragraph of
the Results under the subheading “Rapid identification and susceptibility test performances.”
The correct paragraph is: βLT performed on 164 BSI (P1 and P2 combined) yielded 24 positive,
139 negative and 1 uninterpretable test result due to an incoherent color change of the chromo-
genic test. All positive βLT results were found in non-natural AmpC EB isolates displaying
third generation cephalosporin resistance by complete AST results and subsequently con-
firmed as ESBL producers. In 7 cases, βLT yielded false-negative results since complete AST
and molecular testing identified 6 AmpC producing Escherichia coli and 1 VIMmetallo-beta-
lactamase-producingP. aeruginosa, all resistant to third generation cephalosporin. Globally,
sensitivity and specificity of βLT were respectively 77.4% and 100%. No erroneous or uninter-
pretable results were observedwith PBP2a testing. Performed on 25 S. aureus BSI in P1 and P2,
PBP2a was able to detect all 3 MRSA strains (sensitivity and specificity of 100%). Ultimately, 8
BSI (6 in P1 and 2 in P2) were discarded from outcome analysis due to erroneous/uninterpret-
able rapid test results.
Tables 1 and 2 appear incorrectly in the published article. Please see the correct Tables 1
and 2 and their captions here.
PLOS ONE | DOI:10.1371/journal.pone.0160537 September 22, 2016 1 / 4
a11111
OPENACCESS
Citation: Verroken A, Defourny L, le Polain de
Waroux O, Belkhir L, Laterre P-F, Delme´e M, et al.
(2016) Correction: Clinical Impact of MALDI-TOF
MS Identification and Rapid Susceptibility Testing
on Adequate Antimicrobial Treatment in Sepsis
with Positive Blood Cultures. PLoS ONE 11(9):
e0160537. doi:10.1371/journal.pone.0160537
Published: September 22, 2016
Copyright:© 2016 Verroken et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Table 1. Distribution of microorganisms and main resistances of all bloodstream infections across the three study periods. 3GC, third generation
cephalosporin (cefotaxime, ceftriaxone, ceftazidime); AST, antimicrobial susceptibility testing; BSI, bloodstream infection; carbapenem (imipenem, merope-
nem); ID, identification; P0, pre-intervention period; P1, intervention period 1; P2, intervention period 2. Natural AmpC producers identified during the study
periods: Citrobacter freundii, Enterobacter aerogenes, Enterobacter cloacae, Hafnia alvei, Serratia marcescens. Non-natural AmpC producers identified dur-
ing the study periods: Citrobacter koseri, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Proteus vulgaris, Salmonella spp.
Microorganism Resistance P0 P1 P2
n BSI (%) n BSI (%) n BSI n BSI n BSI (%) n BSI n BSI
final outcome
analysis
final outcome
analysis
with failed
ID
with failed
partial AST
final outcome
analysis
with failed
ID
with failed
partial AST
Gram-positive bacteria 50 (37.3) 40 (35.7) 8 0 44 (28.6) 7 0
Staphylococci 25 22 3 0 24 2 0
Staphylococcus aureus 14 11 1 0 14 0 0
methicillin 1 1 0 - 2 - -
Coagulase negative
Staphylococci
11 11 2 0 10 2 0
Enterococci 12 11 1 0 9 1 0
Streptococci 9 7 2 0 10 4 0
Other Gram-positive
bacteria
4 0 2 0 1 0 0
Gram-negative bacteria 77 (57.5) 71 (63.4) 1 6 107 (69.5) 2 2
Enterobacteriaceae 71 63 0 5 103 1 2
natural AmpC producers 5 6 0 0 11 0 0
3GC 2 1 - - 4 - -
carbapenem 0 0 - - 0 - -
non-natural AmpC
producers
66 57 0 5 92 1 2
3GC 10 6 - 5 18 0 2
carbapenem 0 0 - 0 0 0 0
Non fermenters 6 6 1 1 4 1 0
Pseudomonas aeruginosa 3 4 0 1 3 1 0
3GC 0 0 - 1 0 0 -
carbapenem 0 0 - 1 0 0 -
Other non fermenters 3 2 1 0 1 0 0
Other Gram-negative
bacteria
0 2 - 0 0 0 0
Anaerobes 6 (4.5) 0 (0.0) 6 0 2 (1.3) 6 0
Yeast 1 (0.7) 1 (0.9) 2 0 1 (0.6) 3 0
TOTAL 134 (100) 112 (100) 17 6 154 (100) 18 2
doi:10.1371/journal.pone.0160537.t001
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Table 2. Time to identification and time to partial/complete susceptibility results of all bloodstream
infections during pre-intervention and intervention period 1 and 2.
Time to identification
Phase Method BSI
(n)
Mean time to ID (hours)
P0 TOTAL 134 28.3
Subculture MALDI-TOF MS 134 28.3
Early MALDI-TOF MS - -
Direct MALDI-TOF MS - -
P1 TOTAL 112 10.2
Subculture MALDI-TOF MS 23 15.9
Early MALDI-TOF MS 65 10.6
Direct MALDI-TOF MS 24 3.6
P2 TOTAL 154 10.8
Subculture MALDI-TOF MS 32 17.1
Early MALDI-TOF MS 96 10.7
Direct MALDI-TOF MS 26 4.0
Time to complete susceptibility result
Phase Method BSI
(n)
Mean time to complete AST result (hours)
P0 TOTAL 134 44.7
Phoenix from subculture 58 46.9
Phoenix from young subculture - -
Direct Phoenix 48 28.3
Manual testing from subculture 28 68.3
Manuel testing from young
subculture
- -
P1 TOTAL 112 32.4
Phoenix from subculture 28 41.2
Phoenix from young subculture 23 32.2
Direct Phoenix 45 25.6
Manual testing from subculture 7 49.1
Manuel testing from young
subculture
9 27.3
P2 TOTAL 154 32.6
Phoenix from subculture 34 41.6
Phoenix from young subculture 81 29.9
Direct Phoenix 22 22.2
Manual testing from subculture 8 52.2
Manuel testing from young
subculture
9 30.9
Time to partial susceptibility result
Phase Method BSI
(n)
Mean time to partial susceptibility testing result
(hours)
P1 TOTAL 72 11.8
Culture βLT 20 17.9
Young subculture βLT 29 11.2
Direct βLT 12 3.7
Culture PBP2a 3 15.3
Young subculture PBP2a 6 12
Direct PBP2a 2 2
(Continued )
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Table 2. (Continued)
P2 TOTAL 109 11.7
Culture βLT 29 16.8
Young subculture βLT 51 11.1
Direct βLT 15 3.6
Culture PBP2a 4 20.2
Young subculture PBP2a 9 8.8
Direct PBP2a 1 6
doi:10.1371/journal.pone.0160537.t002
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